Skip to main content

Braveheart Bio, Inc.

corporate_fare Company Profile

Braveheart Bio, Inc.

BRVE·NASDAQ·Life Sciences·CIK 0002131524

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company that develops treatments for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. The company's primary products are BHB-1893 and HRS-1893, which are oral small-molecule cardiac myosin inhibitors (CMIs). These therapies are designed to treat both obstructive HCM and non-obstructive HCM. Braveheart Bio, Inc. was incorporated in 2024 and operates from its base in San Francisco, California.

Braveheart Bio, Inc. (NASDAQ:BRVE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for BRVE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for BRVE spans 8-K, SCHEDULE 13D, 4.

Recent high-impact activity:

  • Braveheart Posts Q3 Loss of $26.5M; $503.5M Cash Funds Runway Into 2029
  • Braveheart Posts $26.5M Q3 Loss, $503.5M Cash Funds Runway Into 2029
  • Braveheart's HRS/BHB-1893 Holds 52-Week Benefit; Fixed-Dose Phase 2b TRUEHEART-HCM Planned
  • Braveheart's HCM Drug Holds Obstruction Gains at 52 Weeks With No Serious Events
  • Braveheart Bio Reports Q2 2026 Results, Initiates Phase 3 LIONHEART-HCM Trial, Extends Cash Runway to 2029

Short Interest & Short Volume

19.63 days to cover

FINRA reported short interest of 5,153,595 shares in BRVE as of the October 30, 2026 settlement, a 5.1% increase from the prior period — about 19.6 days to cover at its recent average daily volume. On November 20, 2026, 93.4% of BRVE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,153,595 shares as of October 30, 2026
Change vs prior period▲ 5.1%
Days to cover19.63 at avg daily volume of 262,573
Daily short volume (FINRA facilities)93.4% of 270,156 shares on November 20, 2026
5-day average short volume95.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for BRVE, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.

1 recent capital raise

IPO Pricing Confirmed · Underwriters' Option

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$20.39
52-week range · as of 2026-11-10 $16.7 – $32
Market cap
$1.83B
Volume
866.7K (1.9× avg)
3-mo avg 465.1K
Live data · 2026-11-21 23:19 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BRVE - Latest Insights

BRVE
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.62
Real-time Price: $20.39 info
Change: +$0.770 (+4%) info
Market Cap: $1.832B info
BRVE
Nov 10, 2026, 4:03 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.62
Real-time Price: $20.39 info
Change: +$0.770 (+4%) info
Market Cap: $1.832B info
BRVE
Nov 06, 2026, 3:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.30
Real-time Price: $20.39 info
Change: +$2.09 (+11%) info
Market Cap: $1.832B info
BRVE
Nov 06, 2026, 3:15 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $18.30
Real-time Price: $20.39 info
Change: +$2.09 (+11%) info
Market Cap: $1.832B info
BRVE
Sep 08, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.41
Real-time Price: $20.39 info
Change: -$9.02 (-31%) info
Market Cap: $1.832B info
BRVE
Aug 14, 2026, 4:55 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $27.03
Real-time Price: $20.39 info
Change: -$6.64 (-25%) info
Market Cap: $1.832B info
BRVE
Aug 11, 2026, 5:53 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $25.01
Real-time Price: $20.39 info
Change: -$4.62 (-18%) info
Market Cap: $1.832B info
BRVE
Aug 11, 2026, 5:27 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $25.01
Real-time Price: $20.39 info
Change: -$4.62 (-18%) info
Market Cap: $1.832B info
BRVE
Aug 07, 2026, 5:25 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $31.00
Real-time Price: $20.39 info
Change: -$10.61 (-34%) info
Market Cap: $1.832B info
BRVE
Aug 07, 2026, 4:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $31.99
Real-time Price: $20.39 info
Change: -$11.60 (-36%) info
Market Cap: $1.832B info
BRVE
Aug 07, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.98
Real-time Price: $20.39 info
Change: -$10.59 (-34%) info
Market Cap: $1.832B info
BRVE
Aug 05, 2026, 10:33 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: N/A
Real-time Price: $20.39 info
Change: N/A info
Market Cap: $1.832B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets